Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: AXIM

AXIM Biotech to Present at Rodman & Renshaw 19th Annual Global Investment Conference in New York City

NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that the Company will be featured as a presenting company at the Rodman & Renshaw 19th Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The conference is being held on September 11-12, 2017 at the Lotte New York Palace Hotel in New York City.

George Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM, will present a corporate update at the Conference on September 11 at 5:05-5:30pm ET in Kennedy II. AXIM’s management will also be holding one-on-one meetings with investors at the Conference.

The Global Investment Conference, which will feature more than 300 public and private companies from around the world, with over 2,000 attendees, offers investors sector tracks devoted to Biotechnology & Healthcare, Metals & Mining, CleanTech, Technology and Media & Telecommunications.

AXIM’s presentation will be available on the corporate website.

About AXIM®
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew Plus™, a CBD-based controlled release chewing gum containing 10mg of hemp-derived CBD, CanChew+ 50™, containing 50 mg of CBD undergoing clinical trials in patients with IBS, and MedChew Rx™, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Investor Relations Contact:
Shiwei Yin, Grayling
Shiwei.Yin@grayling.com
P. +1646 284-9474
Lucia Domville, Grayling
lucia.domville@grayling.com
P. +1646 284-9416

Corporate Contact Info:
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227

Posted in Client News| Tagged , , |
AXIM Biotech, Inc.

AXIM Biotech, Inc. Working on Innovative Response to Global Drug Addiction Crisis

AXIM Biotech, Inc.

AXIM Biotech, Inc. has entered into a clinical study agreement with the renowned University of British Columbia, one of the top three universities in Canada. The study is a clinical trial examining the effectiveness of AXIM’s CBD chewing gum product line as a treatment for psychosis stemming from drug use. This treatment indication is an innovative response to the global drug addiction crisis.

Drug-Induced Psychosis

Psychosis is defined by the mental health community as a disconnect between the individual’s perception and reality itself. Psychosis can result in delusions, hallucinations and other distressing experiences for the affected individual. This condition is also known as substance-induced psychotic disorder, and it may be triggered by drug withdrawal, overdose or interactions between drugs, according to the American Addiction Centers.
As explained by the National Alliance on Mental Illness, approximately 3 out of every 100 people experience one or more psychotic episodes in their lives. The goal of the University of British Columbia trial is to determine whether AXIM’s CBD chewing gum is an effective treatment for the symptoms of substance-induced psychosis.

CBD Gum and Psychosis Treatment

The Clinical Study Agreement between AXIM and the University of British Columbia will focus on the CanChew Plus chewing gum line. This product is formulated with 50mg of CBD and offers a unique delivery mechanism for those suffering from drug-induced psychosis. Chewing gum provides a discreet delivery system and easily controlled doses throughout the day. Until now, patients suffering from drug-induced psychosis have had incredibly limited treatment options.

Drug Addiction and the Opioid Crisis

Drug overdose is the leading cause of accidental death in the United States, and both prescription opioids and heroin account for more than half of accidental overdose deaths. MJNA seeks to offer innovative solutions to those in the medical profession when it comes to addressing this global crisis. Promising results for AXIM’s CBD chewing gum in IBS indications will hopefully open the door for this product to be used for other treatment indications as well.

A new patent on AXIM’s CanChew Plus gum protects chewing gum formulated with both cannabinoids and opioids. This product holds significant promise as a method of combating the global opioid crisis. The irresponsible prescribing of opioids is a leading cause of the opioid epidemic. Many patients obtain legitimate opioid prescriptions for pain when other options, such as cannabinoid-based products or lower-dose opioid analgesics would be more appropriate. It is common for physicians to prescribe high-dose opioids to manage mild pain after an accident or routine dental procedure. The highly addictive potential of opioids means that many of those patients become dependent upon those drugs to manage pain, both physical and psychosomatic, resulting in the development of a long-term addiction as the patient requires higher and higher dosages to maintain the desired state. When used as a treatment for pain alongside a lower dose of opioids, cannabinoids could reduce the risk of opioid dependency and addiction. Because CBD chewing gum is non-addictive, it could offer physicians a safer alternative to traditional opioid prescribing methods.

MJNA in Mexico

HempMeds Mexico has made great strides in the adoption of medical marijuana as a treatment for a variety of treatment indications. In June, Mexico legalized medical marijuana with up to 1-percent THC. Mexico has also given permission for research into the medical use of higher-THC products. In response, MJNA has developed THC-free products to address the needs of consumers in these markets. Recent legalization allows MJNA to offer a fuller spectrum of its products, paving the way for more treatment options for Mexican patients. MJNA’s CBD products have yielded a significant reduction in the rate and severity of seizures in pediatric patients, making them a highly viable option for the treatment of refractory epilepsy.

HempMeds Brasil

In mid-August, MJNA will be meeting with industry leaders in Brazil. The nation has recently welcomed HempMeds Brasil’s products for the treatment of both ALS and psoriasis. Brazilian patients with a prescription for HempMeds Brasil products in these treatment indications may be reimbursed through the Brazilian healthcare system. These products have also been approved for a variety of other therapeutic indications, including migraines, pain, refractory epilepsy, cancer-related pain, Alzheimer’s and diabetes. With such a welcoming response, AXIM hopes to continue to expand its product availability throughout Brazil and the rest of Latin America as well.

Kannaway

Jim Gibson is the newly appointed Vice President of Operations for Kannaway, a subsidiary that offers a diverse liquid-form product line. The full-spectrum liquid line joins the hemp vape line, making it possible for consumers and patients to obtain Kannaway’s products in a variety of formulations and delivery options. Kannaway’s new Tranquility product line is designed to promote sedation and relaxation.

Other 2017 Developments

As MJNA and its subsidiaries continue to expand in terms of clinical trial results, international permissions and product diversification, consumers in a variety of fields will benefit. From over-the-counter product lines to clinical studies on the treatment and prevention of prescription drug addiction, MJNA’s products continue to pioneer new options for physicians and patients alike. The first half of 2017 has yielded promising growth and added to the overall understanding of the versatile capabilities of CBD-based products in a variety of treatment indications.

About the Author

Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit https://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/

Posted in Articles| Tagged , , , , , |

AXIM Biotech Enters Clinical Study Agreement with University of British Columbia to Begin Clinical Trial On CBD Chewing Gum For Treatment of Drug-Related Psychosis

NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) — AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC:AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Clinical Study Agreement (CSA) with the University of British Columbia in Canada to begin a clinical trial with its CanChew Plus® cannabidiol (CBD) chewing gum product to treat drug-induced psychosis in adult patients.

The University will work with Health Canada and their own ethics board to design the trial, which will be conducted at the University of British Columbia, Canada, and will demonstrate the efficacy of AXIM’s chewing gum product composed of 50mg CBD to treat drug-related psychosis.

“This is another major milestone for AXIM, as we embark on this new clinical program on patients suffering from drug-related psychosis using innovative delivery mechanisms containing cannabinoids,” said George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech. “We are excited to be collaborating with the University of British Columbia, one of Canada’s top leading academic institutions, to determine if our CBD chewing gum product will prove to be effective in treating patients for this unmet medical need condition.”

Drug-related psychosis, also known as substance-induced psychotic disorder, is any psychotic episode that is related to the abuse of an intoxicant. According to the National Alliance on Mental Illness, about 3 in every 100 people will experience at least one episode of psychosis in their lifetimes.

The University of British Columbia is a global center for research and teaching, consistently ranked among the 40 best universities in the world, and top three in Canada.

About AXIM®
AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Axim Biotechnologies, Inc. to be materially different from the statements made herein.

LEGAL DISCLOSURE
AXIM® Biotechnologies does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA).
axm

Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P. 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

Investor Relations Contact:
Shiwei Yin, Grayling
Shiwei.Yin@grayling.com
P. +1646 284-9474
Lucia Domville, Grayling
lucia.domville@grayling.com
P. +1646 284-9416

Corporate Contact Info:
North American Address:
18 East 50th Street, 5 Floor
New York, NY 10022
+1 844 294 6246

European Address:
Boelewerf 32, Unit 3
2987 VD Ridderkerk, The Netherlands
+31 10 8209 227

Posted in Client News| Tagged |

Medical Marijuana, Inc Major Investment AXIM Biotech Enters Agreement With Israel-Based CRO To Begin Clinical POC Study For Treatment Of Restless Leg Syndrome

SAN DIEGO, July 27, 2017 /PRNewswire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, today announced that its major investment AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM) has entered into a Services Agreement with an Israel-based contract research organization (CRO) to begin a clinical proof of concept study (POC) with its cannabidiol (CBD) and Gabapentin chewing gum product to treat restless leg syndrome (RLS) in patients.

The PK and double blind, randomized, single-center phase 2 trial will demonstrate the efficacy of AXIM’s chewing gum product composed of Gabapentin and CBD on around 30 study participants to treat RLS. The CRO is conducting the trial in Israel.

“We are proud to support AXIM Biotech as the company continues to identify new clinical applications for its proprietary chewing gum product,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “Research shows that RLS may be related to abnormalities in the nervous system, and even the U.S. Department of Health and Human Services has a patent titled ‘Cannabinoids as Antioxidants and Neuroprotectants.’ We believe that advancements in clinical cannabinoid research may hold keys to helping people experience symptomatic relief from challenging and debilitating neurological disorders.”

Restless leg syndrome (RLS), also known as Willis–Ekbom Disorder (WED), is a condition associated with nocturnal sensorimotor symptoms, or nocturnal spasms of the muscles of the lower extremities, that can result in significant sleep disruption and severe pain. RLS is a prevalent condition, affecting an estimated 3.9–14.3 % of the U.S. population. RLS can negatively affect a patient’s quality of life (QoL) across several domains, such as daytime sleepiness, decreased general health, decreased immune function, stress, and mood.

About Medical Marijuana, Inc.

We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.’s portfolio and investment companies, visit www.medicalmarijuanainc.com.

To see Medical Marijuana, Inc.’s video statement, click here.

Shareholders are also encouraged to visit the Medical Marijuana, Inc. Shop for discounted products.

About AXIM®

AXIM® Biotechnologies, Inc. (AXIM) focuses on the research, development and production of cannabis-based pharmaceutical, nutraceutical and cosmetic products. Our flagship products include CanChew®, a CBD-based controlled release chewing gum, CanChew+ containing 50 mg of CBD undergoing clinical trials in patients with IBS and MedChew Rx, a combination CBD/THC gum that is undergoing clinical trials for the treatment of pain and spasticity associated with multiple sclerosis. We prioritize the well-being of our customers while embracing a solid fiscal strategy. For more information, please visit AXIMBiotech.com.

FORWARD-LOOKING DISCLAIMER AND DISCLOSURES

This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

The statements in this press release have not been evaluated by the Food and Drug Administration (FDA) and are not intended to diagnose, treat or cure any disease.  The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.

CONTACT:
Public Relations Contact:
Andrew Hard
Chief Executive Officer
CMW Media
P: 888-829-0070
andrew.hard@cmwmedia.com
www.cmwmedia.com

SOURCE Medical Marijuana, Inc.

Posted in Client News| Tagged , |
Cannabidiol as a Treatment for Restless Leg Syndrome

AXIM Has Made Major Moves Already in 2017

Cannabidiol as a Treatment for Restless Leg Syndrome

2017 has been an active year for AXIM Biotech (OTCQX: AXIM), with a new services agreement and patent filing updates. AXIM entered into a new services agreement with a contract research organization in Israel, focusing on a clinical proof-of-concept study of its Gabapentin and cannabidiol chewing gum product line. The study will test the effectiveness of this product in the treatment of restless leg syndrome.

About Restless Leg Syndrome

Restless leg syndrome, sometimes known as Willis-Ekbom Disease, is a persistent condition that causes irritating sensations in the legs. Sufferers of this syndrome have the unpleasant urge to move their legs, often during the night when they are trying to sleep. The condition often worsens during long periods of inactivity, having a significant effect on the sufferer’s ability to get adequate rest. It is believed that the cause of restless leg syndrome is in the brain, and it can lead to a significant increase in rates of exhaustion, depression and anxiety. According to researchers, as many as 10 percent of Americans may suffer from restless leg syndrome, and the onset of the condition can occur at any age.

Cannabidiol as a Treatment for Restless Leg Syndrome

Treatment options for those suffering from restless leg syndrome have historically been limited. AXIM CEO Dr. George E. Anastassov explained his hopes that the double-blind study will yield positive indications for AXIM’s chewing gum product in the treatment of this troubling syndrome. Israel is at the cutting edge of cannabinoid research, so the agreement between this organization and AXIM holds significant promise.

The study will include a single-center phase 2 trial conducted by the CRO in Israel. The approximately 30 patients who have agreed to participate in the study will be given AXIM’s CBD and Gabapentin chewing gum to help treat their RLS symptoms. Both pre- and clinical proof-of-concept studies will be conducted in order to determine the effectiveness of the product for this specific treatment indication. AXIM’s CBD chewing gum, known as the CanChew and CanChew+ product lines, are currently in clinical trials for the treatment of IBS as well. MedChew Rx gum is being tested for effectiveness in the treatment of multiple sclerosis symptoms, such as spasticity and pain.

AXIM and the Opioid Epidemic

The opioid epidemic is a global health crisis that is estimated to affect more than 12.5 million people who misuse prescription opioids in the United States alone. Only two million have received a formal opioid addiction diagnosis in the United States, but such addiction results in more than 33,000 deaths and costs billions in damages each year. Nonetheless, irresponsible opioid prescribing practices continue to contribute to this fatal issue. One of the major factors in the opioid addiction epidemic is the lack of education about non-addictive pain treatment options.

Recently, AXIM Biotechnologies announced a patent on its controlled-release CBD chewing gum in the treatment of opioid addiction. The chewing gum may also be helpful when used as a treatment alternative to opioids for chronic pain. Most people become addicted to opioids after first obtaining a legal prescription for the treatment of pain after an accident or another related medical condition. CBD products could be used to treat pain without the risk of addiction that is associated with opioid-based treatment regimens. Opioid addiction therapy using CBD gum involves replacement therapy, in which a non-addictive substance is used in place of the addictive substance to treat pain.

Research supports the theory that cannabinoids, specifically cannabidiol products, can help decrease overpowering cravings for opioids and other narcotics. These cravings are one of the main reasons why opioid addicts have such a difficult time recovering over the long term. Because AXIM’s CBD chewing gum product line is easily metabolized and does not come with the health risks associated with opioids, it is a viable alternative for those suffering from chronic pain and other debilitating conditions. Cannabinoids may also be used in conjunction with opioid treatments to reduce the dosage of opioids the patient needs to take in order to treat pain, thus reducing the risk of opioid addiction.

In addition to the biochemical properties of cannabinoids, research shows that chewing is a stress-reducing action that can be used to improve oral health and increase the release of hormones such as serotonin and dopamine. Many people self-medicate chemical imbalances in these hormones by abusing narcotics. Chewing gum not only improves the bioavailability of cannabinoids, but it provides patients with a healthy alternative habit to indulge that may make overcoming opioid addiction easier.

As the CanChew, CanChew+ and MedChew Rx product lines move forward in clinical trials and development, patients suffering from multiple sclerosis, opioid addiction, restless leg syndrome, and other chronic conditions will have more treatment options to choose from. As the opioid epidemic continues to worsen, the development of non-addictive treatment alternatives is more crucial than ever before.

About the Author

Stuart Smith is the CEO and Founder of SmallCapVoice.com. SmallCapVoice.com. is a recognized corporate investor relations firm, with clients nationwide, known for its ability to help emerging growth companies build a following among retail and institutional investors. SmallCapVoice.com utilizes its stock newsletter to feature its daily stock picks, audio interviews, as well as its clients’ financial news releases. SmallCapVoice.com also offers individual investors all the tools they need to make informed decisions about the stocks they are interested in. Tools like stock charts, stock alerts, and Company Information Sheets can assist with investing in stocks that are traded on the OTC BB and Pink Sheets. To learn more about SmallCapVoice.com and their services, please visit https://smallcapvoice.com/blog/the-small-cap-daily-small-cap-newsletter/

Posted in Articles| Tagged , , |

AXIM Biotechnologies (OTCQB: AXIM) Takes on Opioid Epidemic with New Patent — SECFilings.com

AXIM is a major investment of Medical Marijuana, Inc. (OTC PINK: MJNA), the first publicly traded cannabis company

REDONDO BEACH, CA–(Marketwired – Jun 27, 2017) – SECFilings.com, a leading financial news and information portal offering free real time public company filing alerts, announces the publication of an article covering AXIM® Biotechnologies Inc. (OTCQB: AXIM) and its recent patent on cannabinoid and opioid combinations in chewing gum. Medical Marijuana Inc. (OTC PINK: MJNA), the first publicly traded cannabis company, holds about 22.7 million shares of AXIM Biotech stock.

More than 12.5 million people misuse prescription opioids, according to the U.S. Department of Health and Human Services, while two million people have been formally diagnosed with an addiction. These addictions cause $78.5 billion in economic damages each year and lead to more than 33,000 deaths from overdose each year. Despite these issues, physicians have few alternatives for prescribing opioids for pain management.

New Patent Addition

AXIM Biotechnologies recently announced a patent on chewing gum with a controlled release of cannabinoids and opioid agonists and/or antagonists for addiction and/or dependence treatment. In addition, the same chewing gum formulation may be used for the treatment of chronic pain as an alternative to opioid-only treatment options, which could represent an enormous end market for future product lines.

“Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies,” said AXIM Biotech CEO Dr. George E. Anastassov, MD, DDS, MBA. “Opioid addiction therapy depends on a variety of techniques. One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the cravings and reduces withdrawal symptoms.”

There is evidence that cannabinoids — and cannabidiol (CBD) in particular — may decrease cravings for narcotics. The company aims to provide these cannabinoids in microencapsulated form, which may improve its chewing gum’s taste, prevent binding with the gum’s base, control release during mastication (chewing), and further improve the bioavailability of the cannabinoids once entering the gastrointestinal tract.

Reuters, Fortune, CNBC, and others featured the story.

Breakthrough Product

Opioid addiction is often chemically treated using a combination of two approaches. First, agonists like methadone or buprenorphine activate opioid receptors in the brain to produce a substitute opioid effect with less potential for addiction. Second, antagonists like naltrexone and naloxone block opioids by attaching to the same opioid receptors without activating them, which reduces the side effects of the agonists and reducing addiction over time.

The addition of cannabinoids to this treatment strategy could prove to be a breakthrough because cannabinoids may help with pain management. Often times, a large struggle with overcoming an opioid addiction is dealing with the resulting increase in pain from the reduction in opioid consumption. Cannabinoids can help fill the void in a way that avoids any addictive properties and enhances the overall patient wellbeing.

These same properties mean that cannabinoids may be able to act as an opioid substitute in first-line pain medications. For instance, a patient that would normally take 100% opioids may be able to take just 50% opioids and 50% cannabinoids, reducing the likelihood of an opioid addiction and the other negative side effects associated with high levels of opioids. This may be particularly impactful in cases of chronic pain management.

The company’s other clinical programs include chewing gum formulations for prescription and over-the-counter indications, as well as topical applications, suppositories, and ophthalmic preparations. Its CanChew Plus® and AX-1602 represent its most advanced programs that are heading into POC Phase 2A clinical trials in Irritable Bowel Syndrome and Psoriasis — two multi-billion dollar markets that are ripe for innovation.

Please follow the link to read the full article: http://analysis.secfilings.com/articles/181-axim-biotechnologies-otcqb-axim-takes-on-opioid-epidemic-with-new-patent

About SECFilings.com

Founded in 2004, SECFilings.com provides free real time filing alerts to over 600,000 registered members and offers services to help public companies grow their audience of interested investors.

Disclaimer:

Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns SECFilings.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://secfilings.com/Disclaimer.aspx.

Contact Information

SECFilings.com
Paul Archie
406-862-2242
parchie@secfilings.com

Posted in Client News| Tagged , |